Effect of Cell Therapy on Recovery of Cognitive Functions in Rats during the Delayed Period after Brain Injury

Roshal, L. M.; Tzyb, A. F.; Павлова, Л. М.; Soushkevitch, G. N.; Semenova, J. B.; Javoronkov, L. P.; Колганова, О. И.; Konoplyannikov, A. G.; Шевчук, А. С.; Yujakov, V. V.; Карасева, О. В.; Ivanova, T. F.; Chernyshova, T. A.; Konoplyannikova, O. A.; Bandurko, L.N.; Marey, Maria V.; Сухих, Г. Т.

doi:10.1007/s10517-009-0642-8

Cited by 6 publications

(5 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies revealed that MSC therapy may induce neurologic functional recovery in patients with TBI (27). The proliferotropic, angiogenic, neuroprotective, neutrophic, and regenerative effects of MSCs in rat trauma models were demonstrated in previous studies (16,33).…”

Section: Discussionmentioning

confidence: 93%

Bone marrow mesenchymal stem cell transplantation in acute brain trauma

Park¹,

Yoon²,

An³

2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Bone marrow mesenchymal stem cell transplantation in acute brain trauma

Park¹,

Yoon²,

An³

2013

Nuklearmedizin

View full text Add to dashboard Cite

show abstract

“…The “Beijing Declaration of IANR” (agreed upon at the IANR 2015 Conference in Tehran) declared as its fundamental tenet that “functional recovery is possible after central nervous system (CNS) injury and neurodegeneration” and noted that “cell therapies may become a key clinical therapeutic option for acute, subacute and/or chronic CNS diseases or damage” 5 . More than 30 types of cells have been identified through preclinical studies as having the capacity for neurorestoration 6 – 66 .…”

Section: Introductionmentioning

confidence: 99%

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

et al. 2018

View full text Add to dashboard Cite

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.

show abstract

“…46 even without immunosuppression. Transient immunosuppression was shown to be sufficient to support engraftment and transplanted derived neurons were reportedly present 6 months post transplantation.…”

Section: Step 2 Immunosuppressionmentioning

confidence: 99%

One Step at a Time, Stem Cell Therapy for Traumatic Brain Injury Needs Two More Breakthroughs

Gajavelli¹

2016

JSRT

View full text Add to dashboard Cite

26As of 2015, a total of 49 ALS patients have received NSI-566 cells. Both the cells and surgery were well tolerated and the ALS studies reported a 47% responder rate with decline in disease progression and improved grip strength. Stem cells inc., on the other hand lost a patent dispute to NSI and recently closed operations.J Stem Cell Res Ther. 2016;1(4):160-164. 160© 2016 Shyam. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.One step at a time, stem cell therapy for traumatic brain injury needs two more breakthroughs Step 2 ImmunosuppressionTransplantation of the cells conferred benefits such as restoration of injured neuronal morphology 45 and cognitive function. 46 even without immunosuppression. Transient immunosuppression was shown to be sufficient to support engraftment and transplanted derived neurons were reportedly present 6 months post transplantation. 47 However, no data quantifying either engraftment or behavior modification were presented. Such studies were limited by cyclosporine mediated immunosuppression which resulted in persistence of barriers to engraftment and demonstration of effectiveness of the approach. 48-50The initial optimism was replaced by skepticism if the therapeutic potential of neural stem cells: greater in people's perception than in their brains. 51,52 The US Food and Drug Administration (FDA; Rockville, MD) guidelines on preclinical assessment of cell therapies in the publication "Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products".53,54 A review of literature shows human cell therapy in rat TBI that measure cognitive benefit have not addressed donor cell fate past one-month posttransplantation. 1,55 Further the experts in the field recommended that 8-week survival period prior to assessments would allow sufficient time for differentiation and integration of human neural stem cells with the host and possibly validate the presumed mechanism of action. 1,26The successful preclinical ALS, SCI and stroke studies. 40,41,44,56 have employed a different immunosuppression technique that was pioneered by Hefferan et al. 40 This technique relies on three agents namely: mycophenylate mofetil, tacrolimus and methyl prednisolone. The combination has been found to be superior to cyclosporine, a standard immunosuppressant between 1999-2012. Step 3 Mechanism of actionHowever, due to the lack of exact mechanism of action still precludes attempts to move neural stem cell therapy to the clinic. 26Paul Lu et al. 41 demonstrated the mechanism of regeneration in spinal cord injury models. 41 Axonal growth was partially dependent on mammalian target of rapamycin (mTOR), but not Nogo signaling. Grafted neurons supported formation of electrophysiological relays across sites of complete spinal transection, resulting in functional recovery. The recovery was lost subsequent to re-transection of the spinal cord....

show abstract

Effect of Cell Therapy on Recovery of Cognitive Functions in Rats during the Delayed Period after Brain Injury

Cited by 6 publications

References 9 publications

Bone marrow mesenchymal stem cell transplantation in acute brain trauma

Bone marrow mesenchymal stem cell transplantation in acute brain trauma

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

One Step at a Time, Stem Cell Therapy for Traumatic Brain Injury Needs Two More Breakthroughs

Contact Info

Product

Resources

About